ALEMS — European Medical Solutions SA Share News
0.000.00%
Last trade - 00:00- €16.25m
- €31.86m
- €49.92m
Brief: Asit Biotech Publishes Phase IIb Clinical Results With gp-ASIT+
Brief: Asit Biotech announces grant from European Patent Office related to ASIT+ allergy immunotherapy product candidates
Brief: Asit Biotech launches additional fund raising of up to 3 million euros
Brief: Asit Biotech says active ingredients used in ASIT+ granted European patent
Brief: Asit biotech announces publication of its first clinical data with gp-ASIT+
Brief: Asit Biotech H1 loss for the period narrows to 6.8 million euros
Brief: Asit Biotech announces approval of follow-up study of clinical trial with hdm-asit+
Brief: Asit Biotech discloses comments from the PEI on BTT009
Brief: Asit Biotech FY net loss widens to 12.3 million euros
Brief: Asit Biotech announces that it has achieved primary endpoint of phase I/IIa clinical trial with its hdm-ASIT+ product candidate for house dust mite rhinitis
Brief: Asit Biotech to appoint Gerd Zettlmeissl as Chairman of the Board
Brief: ASIT Biotech reports results of phase III clinical trial
Brief: Asit Biotech announces last patient last visit in phase IIa clinical study with hdm-ASIT+ product
Brief: Asit Biotech receives 6 mln euros in funding from the Walloon govt
Brief: Asit Biotech presents ASIT+ benefits in treating grass pollen rhinitis
Brief: Asit Biotech gets constructive FDA recommendations regarding gp-ASIT+
Brief: Asit Biotech H1 net loss widens to 7.5 million euros
Brief: ASIT Biotech announces the initiation of a phase 2a clinical study of its second product candidate hdm-ASIT+(TM) for House Dust Mite Rhinitis
Brief: Euronext announces quarterly revision of Belgian indices